AGM/EGMApr 26, 2026, 05:29 AM
LQDA to Hold 2026 Annual Meeting on June 16; YUTREPIA Success
AI Summary
Liquidia Corporation announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026. Stockholders will vote on the election of three Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and an advisory vote on executive compensation. The company highlighted the transcendent commercial success of YUTREPIA, which generated hundreds of millions in net product sales and led to profitability within four months of launch, ending the year with $190.7 million in cash. Liquidia plans to invest in future growth by initiating six new clinical studies for YUTREPIA and advancing L606 into its pivotal Phase 3 study.
Key Highlights
- Annual Meeting of Stockholders to be held virtually on June 16, 2026, at 4:30 p.m. ET.
- Stockholders to vote on electing three Class II directors for a term expiring in 2029.
- Proposal to ratify PricewaterhouseCoopers LLP as independent auditor for 2026.
- Advisory vote on the compensation of named executive officers.
- YUTREPIA generated hundreds of millions in net product sales within one year of launch.
- Company achieved profitability within four months of YUTREPIA launch.
- Ended the year with $190.7 million in cash and positive cash flow.
- Plans to initiate six new clinical studies in 2026 for YUTREPIA and L606.
- L606, an extended-release treprostinil, is advancing into pivotal Phase 3 RE-SPIRE study.